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Context. Upper gastrointestinal cancer is associated with a poor prognosis. The
multidimensional problems of incurable patients require close monitoring and
frequent support, which cannot sufficiently be provided during conventional one
to two month follow-up visits to the outpatient clinic.
Objectives. To compare nurse-led follow-up at home with conventional medical
follow-up in the outpatient clinic for patients with incurable primary or recurrent
esophageal, pancreatic, or hepatobiliary cancer.
Methods. Patients were randomized to nurse-led follow-up at home or
conventional medical follow-up in the outpatient clinic. Outcome parameters
were quality of life (QoL), patient satisfaction, and health care consumption,
measured by different questionnaires at one and a half and four months after
randomization. As well, cost analyses were done for both follow-up strategies in
the first four months.
Results. In total, 138 patients were randomized, of which 66 (48%) were
evaluable. At baseline, both groups were similar with respect to clinical and
sociodemographic characteristics and health-related QoL. Patients in the nurse-
led follow-up group were significantly more satisfied with the visits, whereas QoL
and health care consumption within the first four months were comparable
between the two groups. Nurse-led follow-up was less expensive than conventional
medical follow-up. However, the total costs for the first four months of follow-up in
this study were higher in the nurse-led follow-up group because of a higher
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gastrointestinalIntroduction
Symptoms of upper gastrointestinal (GI)
cancer tend to appear at a relatively late stage
of the disease.1e3 This explains why these
cancers are generally associated with a poor
prognosis. Moreover, many patients develop
recurrent disease after surgical resection.
When curative options are no longer available,
one year survival rates are less than 15%.4,5 For
patients with unresectable or recurrent esoph-
ageal, pancreatic, or hepatobiliary cancer, no
curative options are available. Median survival
of these patients is less than 10 months. Pallia-
tive treatment aims to improve the quality of
life (QoL) of patients and their families by
the prevention, early identification, and treat-
ment of pain and other physical, psychosocial,
and spiritual problems.6 The high prevalence
of these multiple problems in patients at a pal-
liative stage of their disease underlines the
need for close monitoring and support.7e10
The interval between follow-up visits, there-
fore, depends on the adequacy of controlling
these multidimensional symptoms. Currently,
patients are usually followed by means of regu-
lar visits to the outpatient clinic. The fre-
quency of these visits is low in our hospital,
with an average of once every one to three
months, or even no follow-up. Outpatient
clinic visits are a burden for many palliative
care patients, among others, in terms of travel-
ing distance while physically unfit. In addition,
the short contact during these visits often
leaves little time to deal with all issues and con-
cerns.11,12 We performed a study in which 109
patients, after intentionally curative surgery for
esophageal or gastric cardia cancer, were ran-
domized to standard follow-up by surgeons at
the outpatient clinic or by regular home visitsof a specialist nurse.13 We found that nurses
were able to perform follow-up of patients in
their homes, and we found positive effects on
QoL and satisfaction of patients and spouses.
In addition, this follow-up strategy seemed to
be cost-effective compared with standard
follow-up at the outpatient clinic.14 Based on
these results, we hypothesized that nurse-led
home visits could have the same positive ef-
fects for patients in the palliative stage of the
disease. This study, therefore, evaluated
whether nurse-led follow-up by home visits
could be an acceptable alternative to our stan-
dard medical follow-up at the outpatient clinic
by a physician for upper GI cancer patients
and their relatives receiving palliative care.Methods
Participants and Allocation
Consecutive patients with unresectable or
recurrent upper GI cancer were recruited
from the Departments of Oncology, Gastroen-
terology and Surgery of the Erasmus MCd
University Medical Center Rotterdam between
June 2006 and August 2009. The Erasmus MC
is a large university-affiliated tertiary referral
center in The Netherlands for patients with
esophageal, pancreatic, and hepatobiliary can-
cer. Patients were eligible when a multidisci-
plinary panel concluded that a curative
modality or disease modifying anti-tumor ther-
apy (i.e., palliative chemotherapy, radiother-
apy, or surgery) was not or no longer
possible. Excluded were patients who were ad-
mitted to a nursing home or hospice, patients
who could not be followed by a physician at
the outpatient clinic of the Erasmus MC, and
patients who were unable to understand the
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naires. Patients were followed for a maximum
period of 13 months from inclusion to either
death or loss to follow-up. The institutional re-
view board of the hospital approved this study,
and written informed consent was obtained
from all patients.
After obtaining informed consent, patients
were randomized to conventional medical
follow-up at the outpatient clinic or to nurse-
led follow-up at home. Randomization was per-
formed using permutated blocks of size 4 and
6, in random order, and stratified by group of
esophageal or gastric cancer, duodenal or
pancreatic cancer, and hepatobiliary cancer.
Patients were assigned to their randomized al-
location by the study coordinator using a cen-
tral telephone or fax number. Patients were
asked to nominate a relative who was most in-
volved in their care. If available, this relative
also was contacted by the study coordinator
and asked for additional informed consent.Interventions
Nurse-Led Follow-Up. Nurse-led follow-up was
performed by home visits of a specialist nurse,
with more than 10 years’ experience in oncol-
ogy nursing care. Follow-up was done at
14 days and then monthly after randomization,
up to 13 months or death. If necessary, tele-
phone contact was possible between visits.
The protocol for the nurse-led follow-up is
shown in the Appendix.
The nurse-led care focused primarily on re-
lief of patients’ suffering and complaints. For
repeated assessment of the actual situation,
the nurse used a modified version of the Ed-
monton Symptom Assessment System ques-
tionnaire.15 The nurse worked under the
guidance of the attending medical specialist(s)
at the Erasmus MC and had regular contact
with both the attending physician and the pa-
tient’s general practitioner (GP).Conventional Medical Follow-Up. Conventional
medical follow-up comprised scheduled ap-
pointments at the outpatient clinic of the Eras-
mus MC. Follow-up was performed one month
and then every two months after randomiza-
tion, up to 13 months or death. If patients
were unable to come to the hospital, appoint-
ments could be done by telephone.Nurse-led care was different as compared
with conventional medical follow-up. Patients
in this group were only referred back to the
medical specialist when a medical intervention
was indicated that could not be done by the
GP (Appendix). In both patient groups, in
case of symptoms and a subsequent palliative
treatment, visits were frequently made to eval-
uate the effect of this treatment on symptom
burden.
Questionnaires
At baseline, patient sociodemographics,
clinical characteristics, and preference for
follow-up were assessed. Outcome measures
were based on structured questionnaires as-
sessing patient (and relative) satisfaction,
health-related QoL (HRQoL), and health
care consumption (use of GP and hospital
admission).
HRQoL. HRQoL was assessed using two mea-
sures. The first was the generic EuroQoL-5D,16
which contains a five-item classifier plus a visual
analogue scale of overall health status. The sec-
ond was the generic EuropeanOrganization for
Research and Treatment of Cancer Quality of
Life Questionnaire Core 30 (EORTC QLQ-
C30) measure,17 which incorporates nine
multi-item scales: five functional scales (physi-
cal, role, emotional, cognitive, social), three
symptom scales (nausea/vomiting, fatigue,
pain), six single items (dyspnea, insomnia, ap-
petite loss, constipation, diarrhea, and financial
difficulties), and a global health/QoL scale. In
addition to these QoL measurements, the de-
grees of anxiety and depression were assessed
with the Hospital Anxiety and Depression
Scale,18,19 and pain intensity was measured on
a numerical rating scale from 0 (no pain) to
10 (maximum pain imaginable).
Patient Satisfaction. As no specific validated
Dutch questionnaire was available to assess pa-
tient satisfaction in this setting, a satisfaction
questionnaire was developed for patients as
well as their relatives, based on the question-
naire of Verschuur et al.13 The questionnaire
in the present study contained three general
propositions related to the follow-up proce-
dure (rated as agree, neutral, not agree),
nine questions with regard to satisfaction
with the content of the visit (rated as being
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very dissatisfied), and a rating from 1 to 10
for overall satisfaction and the burden of the
visit.
Health Care Consumption. Patients or their rel-
atives provided a monthly overview by means
of a questionnaire regarding all contacts with
GP and (re)admissions to the hospital.
Data Collection
The initial assessment at randomization was
performed in the outpatient clinic or on the
hospital ward. HRQoL and satisfaction ques-
tionnaires for patients, and the latter for rela-
tives as well, were completed at one and
a half, four, seven, 10, and 13 months after ran-
domization (postal mailing). GP visits and hos-
pital admissions were assessed monthly, also by
postal mailing. Patients or relatives were con-
tacted by telephone if the questionnaires
were not returned on time. If desired, the
questionnaires were completed with the help
of the study coordinator at home or in the out-
patient clinic.
Statistical Analysis
Analyses were performed on an intention-to-
treat basis. Patients could be evaluated if they
completed at least one questionnaire regard-
ing QoL. First, we estimated the number of pa-
tients at each point of data collection because
we expected a decline as a result of death be-
fore the endpoint of the study (13 months).
Furthermore, we analyzed the differences in
scores between baseline and each point of
data collection.
We ignored missing items on QoL and satis-
faction questionnaires when making the calcu-
lations, whenever at least half the items for
multi-item scales were completed. The assump-
tion was that these likely occurred at random.
Otherwise, we registered the scores as missing.
To investigate the robustness of the conclu-
sions, we performed a sensitivity analysis on
the results of EORTC QLQ-C30 (primary out-
come) with two other datasets: 1) dataset in-
cluding missing values analysis, in which
missing values are replaced with the mean of
all other values in the same group (nurse-led
or conventional follow-up) and 2) dataset ex-
cluding missing values from analysis, bydeleting the patient with one or more missing
values on a questionnaire.
The results were expressed as mean  SD
and medians and interquartile range (IQR) if
the scores were not normally distributed. Sur-
vival time from inclusion to death was calcu-
lated by using the Kaplan-Meier method.
Comparisons of nominal variables were made
using the Chi-square test, whereas compari-
sons of ordinal variables were made using the
Mann-Whitney U test. Numerical variables
were compared with Student’s t-test (normal
distribution) or the Mann-Whitney U test (no
normal distribution). For calculating costs of
both follow-up strategies, we estimated time
and travel prices for one visit and for the actual
costs incurred in this study for four months’
follow-up. Standard costs as determined for
cost research in health care20 were used as
the basis for these calculations, with all costs
reported in Euros. For all analyses, to mini-
mize the impact of multiple comparisons,
a two-sided P-value of less than 0.01 was consid-
ered statistically significant. Calculations were
performed with SPSS, version 14.0 (SPSS
Inc., Chicago, IL). According to a power calcu-
lation in advance, we calculated that two
groups of 50 patients would be sufficient for
a difference of approximately .56 SD on the
standardized EuroQoL-5D, with a two-sided
Type 1 error rate of 0.05 and a statistical power
of 80%. Taking into account the loss to follow-
up, a total of 150 patients was considered to be
sufficient.Results
Patient Demographics
Patients Who Refused vs. Consented. In total,
204 patients were eligible and informed about
the study, and 68% (n ¼ 138) agreed to partic-
ipate (Fig. 1). Reasons for refusal to participate
were that the study was considered too burden-
some (53%), there was no need for hospital-
based follow-up (33%), and the patient
preferred a doctor-led follow-up (14%).
Patients With vs. Without Follow-Up Data. Of
the 138 patients allocated to either nurse-led
follow-up or outpatient clinic follow-up, 66
(48%) completed at least one questionnaire
regarding QoL and satisfaction within four
 Eligibility (n=204)
Refused to 
participate (n=66)
Randomized 
(n=138)
Allocated to nurse-led follow-up at 
home (n=70)
Allocated to physician-led follow-
up at the outpatient clinic (n=68)
Baseline (n=63)
Patient- and disease characteristics
Quality of life
1½ month (n=36)*
Quality of life (n=36)
Satisfaction (n=35)
Health care consumption (n=34)
4 months (n=21)
Quality of life (n=20)
Satisfaction (n=21)
Baseline (n=61)
Patient- and disease characteristics
Quality of life
Drop out (n=15)
Refused to 
remain (n=3)
Died (n=12)
Drop out (n=27)
Refused to 
remain (n=5)
Died (n=22)
* = evaluable patients
** = 2 pts only had follow-up data at 4 months
Baseline
questionnaires not 
completed (n=7)
Baseline 
questionnaires not 
completed (n=7)
Drop out (n=31)
Refused to 
remain (n=14)
Died (n=17)
Study completed 13 months (n=3)
Drop out (n=18)
Refused to 
remain (n=0)
Died (n=18)
1½ month (n=30)*
Quality of life (n=28)**
Satisfaction (n=22)
Health care consumption (n=29)
4 months (n=17)
Quality of life (n=16)
Satisfaction (n=17)
Study completed 13 months (n=2)
Drop out (n=13)
Refused to 
remain (n=4)
Died (n=9)
Drop out (n=15)
Refused to 
remain (n=5)
Died (n=10)
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Fig. 1. Flow diagram of recruitment.
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ups, 30 outpatient clinic follow-ups). The re-
mainder of included patients (n ¼ 72) were
closer to death at inclusion (median survival
1.6 month [IQR 0.92e3.02] vs. patients with
follow-up data, median survival 6.8 months
[IQR 3.90e10.50]; P ¼ 0.00) and they less of-
ten had a relative to provide input for the sat-
isfaction questionnaire (drop-out patients with
relative, n ¼ 38 [53%] vs. patients with follow-
up data with relative, n ¼ 47 [71%]; P ¼ 0.03).
At baseline, the patients without follow-up data
scored worse on all QoL items/scales, exceptfor financial problems, than the patients with
follow-up data.
Patients With Nurse-Led Follow-Up vs. Conventional
Medical Follow-Up. Our findings reflect patient
satisfaction, QoL, and health care consump-
tion in the first four months after inclusion,
because at later follow-up, too few patients re-
mained alive to allow for meaningful analyses.
Regarding the 66 patients with follow-up data,
there was no statistically significant difference
between the two follow-up strategy groups
according to the demographic or clinical
Table 1
Characteristics of 66 Patients With Unresectable or Recurrent Esophagus, Pancreas, or Hepatobiliary Cancer
With Data From at Least Baseline and One Follow-Upa for All Outcomes
Characteristics
Nurse-Led
Follow-Up (n ¼ 36)
Outpatient Clinic
Follow-Up (n ¼ 30)
P-valuen (%) n (%)
Age, years; mean (SD) 67 (10.4) 64 (12.0) 0.37b
Sex: male 22 (61) 18 (60) 0.93c
Primary tumor site 0.52c
Esophagus/gastric 18 (50) 16 (53)
Pancreatic/duodenum 10 (28) 5 (17)
Hepatic/common bile duct 8 (22) 9 (30)
Main indication for palliative care 0.88c
Unresectable tumor 5 (14) 6 (20)
Inoperable disease 2 (6) 2 (7)
Distant metastases 4 (11) 3 (10)
Recurrence 3 (8) 4 (13)
Unknown 22 (61) 15 (50)
Preference for follow-up strategy at baseline 0.36c
Nurse-led follow-up at home 27 (75) 17 (57)
Physician-led follow-up at the outpatient clinic 1 (3) 1 (3)
No preference 8 (22) 12 (40)
Marital status: single/separated/divorced/widowed 11 (31) 7 (23) 0.51c
No religion 14 (39) 12 (40) 0.97c
Highest education 0.25d
Elementary school 20 (56) 11 (37)
Intermediate school (VMBO/MBO)e 7 (19) 10 (33)
Higher school (HAVO/HBO/VWO/university)f 9 (25) 7 (23)
Unknown d 1 (3)
Travel time to the hospital; km, median (IQR) 38 (10.3e64.3) 19 (13.8e29.3) 0.09d
IQR ¼ interquartile range.
aAt one-and-a-half or four-month follow-up.
bStudent’s t-test.
cChi-square test.
dMann-Whitney U test.
eVMBO ¼ pre-vocational secondary education (VMBO) which is usually an introduction to middle vocational education (MBO).
fHAVO ¼ Senior general secondary education qualifies students to enter higher professional education (HBO). VWO ¼ Pre-university education
prepares students for academic studies at university level (WO) VWO includes Gymnasium (Latin and Greek is compulsory), Atheneum (Latin or
Greek is compulsory), Lyceum (Latin and Greek are optional).
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ence was found for travel distance to the hospi-
tal. Patients with at least one follow-up
allocated to conventional medical follow-up
at the outpatient clinic had less travel distance
(median 19 km, IQR 13.8e29.3) than patients
allocated to the nurse-led follow-up at home
(median 38 km, IQR 10.3e64.3). The median
follow-up time was 6 months in both groups,
and there was no significant difference in sur-
vival between both groups.
Patients in the nurse-led follow-up group
had an overall median survival of 6.3 months
(IQR 4.7e7.9) vs. median 6.8 months (IQR
3.9e9.6) (P ¼ 0.87) in the conventional medi-
cal follow-up arm. More patients in the con-
ventional medical follow-up group refused
further participation in the trial before the
official endpoint of the study (death or 13
months): nine patients (8%) in the conven-
tional medical follow-up group vs. threepatients (30%) in the nurse-led follow-up
group (P ¼ 0.02).
HRQoL
The difference between the median
EuroQoL-5D index score in the nurse-led fol-
low-up group and the conventional medical
follow-up group was not significant at both
time points (0.78, IQR 0.31e0.88 at one and
a half months and 0.78, IQR 0.33e0.84 at
four months vs. 0.67, IQR 0.33e0.78 at one
and a half months and 0.69, IQR 0.31e0.81
at four months, respectively). Results from
EORTC QLQ-C30 show that at baseline pa-
tients in the nurse-led follow-up group vs. the
conventional medical follow-up group had
less symptoms of diarrhea (median 0.0, IQR
0.0e0.0 vs. median 0.0, IQR 0.0e33.3;
P ¼ 0.09), financial difficulties (median 0.0,
IQR 0.0e0.0 vs. median 0.0, IQR 0.0e0.0;
P ¼ 0.06), and had better cognitive
Table 2
Satisfaction of Patients and Relatives With Follow-Up Strategy At One-and-a-Half Month Follow-Up
Statement/Item from Satisfaction
Questionnaire
Mean (SD) Score at One-and-a-Half Month Follow-Up
Patients Relatives
Nurse-Led
Follow-Up
Outpatient Clinic
Follow-Up
P-valuea
Nurse-Led
Follow-Up
Outpatient
Clinic
Follow-Up
P-valuean ¼ 35 n ¼ 22 n ¼ 30 n ¼ 19
Agreement with statement (1e3, 1 ¼ most agreed)
Visit proceeded as expected 1.0 (0.00) 1.2 (0.59) 0.07 1.1 (0.37) 1.3 (0.65) 0.18
I had chosen the same follow-up for myself 1.0 (0.00) 2.3 (0.90) <0.001 1.0 (0.00) 2.2 (0.98) <0.001
They take enough time for me 1.0 (0.00) 1.1 (0.43) 0.21 1.1 (0.31) 1.2 (0.63) 0.42
Rating of item (1e10, 10 ¼ best)
Overall satisfaction 8.4 (0.95) 7.5 (2.02) 0.02 8.0 (1.13) 6.8 (2.32) 0.02
Extent of burden follow-up visit 8.4 (1.90) 6.0 (2.65) <0.001 8.4 (1.56) 4.9 (2.44) <0.001
Satisfaction on item (1e5, 1 ¼ most satisfied)
All items listed below together 1.6 (0.42) 1.8 (0.54) 0.14 1.8 (0.39) 2.1 (0.77) 0.08
Care is readily available 1.5 (0.70) 2.1 (1.04) 0.01 1.7 (0.76) 2.4 (1.26) 0.01
Knowledge of the physician/nurse 1.6 (0.50) 1.7 (0.72) 0.35 1.8 (0.50) 1.8 (0.75) 0.91
Confidence given by physician/nurse 1.5 (0.51) 1.6 (0.73) 0.36 1.7 (0.54) 2.0 (1.03) 0.18
Management of physical complaints 1.8 (0.54) 1.7 (0.70) 0.69 1.8 (0.50) 1.9 (0.91) 0.44
Information given by physician/nurse 1.7 (0.48) 1.7 (0.47) 0.75 1.8 (0.64) 1.9 (0.87) 0.40
Advices given by physician/nurse 1.6 (0.49) 1.8 (0.70) 0.37 1.8 (0.38) 2.1 (0.97) 0.27
Answers you get from physician/nurse 1.6 (0.50) 1.8 (0.69) 0.21 1.8 (0.41) 2.0 (0.82) 0.25
How the physician/nurse involve you in
care planning
1.7 (0.54) 1.8 (0.66) 0.32 1.9 (0.45) 2.2 (1.03) 0.12
Support you receive from physician/nurse 1.5 (0.51) 1.8 (0.66) 0.08 1.8 (0.50) 2.3 (1.15) 0.06
The values highlighted in bold are statistically significant (P < 0.01).
aStudent’s t-test.
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median 83.3, IQR 50.0e100; P ¼ 0.09), respec-
tively. These differences were no longer pres-
ent during follow-up. Patients in the
conventional medical follow-up group were
more often depressed (median 8.5, IQR
5.0e11.0 vs. median 5.0, IQR 2.0e11.0;
P ¼ 0.15) after one and a half months of
follow-up, and in these patients, loss of appe-
tite was less common (median 0.0, IQR
0.0e66.7 vs. median 66.7, IQR 8.3e100,
P ¼ 0.05) after four months of follow-up.
Patient and Relative Satisfaction
Both patients and their relatives in the
nurse-led group were more satisfied with their
follow-up than those receiving conventional
medical follow-up (Tables 2 and 3). Mean over-
all patient satisfaction at one and a half and
four months was 8.4  0.95 and 8.5  1.03, re-
spectively, for the nurse-led follow-up group
compared with 7.5  2.02 and 7.1  1.18, re-
spectively, for the conventional medical
follow-up group (P ¼ 0.02 and <0.001, respec-
tively). Mean overall relative satisfaction at one
and a half and four months was 8.0  1.13 and
8.5  0.98, respectively, for the nurse-ledfollow-up group compared with 6.8  2.32
and 6.9  2.38, respectively, for the conven-
tional medical follow-up group (P ¼ 0.02 and
0.01, respectively).
At both time points, patients and relatives in
the conventional medical follow-up group less
frequently agreed on the statement that they
had opted for this follow-up strategy when
given a choice (P < 0.001), and they evaluated
the conventional medical follow-up as more
burdensome (P < 0.001). According to the
visits, patients in the nurse-led follow-up group
were more satisfied about the following as-
pects: advice and information given by the
care provider (at four month follow-up,
P < 0.001) and the involvement of the patient
in his or her own care planning (at four month
follow-up, P < 0.001). For these items, patients
in the conventional medical follow-up group
became less satisfied over time, whereas the
scores remained the same in the nurse-led
follow-up group.
Health Care Use
In total, 268 visits were made in the nurse-
led group (157 home visits, 95 telephone con-
sults, and 16 referral visits to the outpatient
Table 3
Satisfaction of Patients and Relatives With Follow-Up Strategy At Four-Month Follow-Up
Statement/Item from Satisfaction
Questionnaire
Mean (SD) Score at Four-Month Follow-Up
Patients Relatives
Nurse-Led
Follow-Up
Outpatient
Clinic
Follow-Up
P-valuea
Nurse-Led
Follow-Up
Outpatient
Clinic
Follow-Up
P-valuean ¼ 21 n ¼ 17 n ¼ 21 n ¼ 12
Agreement with statement (1e3, 1 ¼ highly agree)
Visit is proceeded as expected 1.0 (0.00) 1.4 (0.70) 0.01 1.0 (0.00) 1.5 (0.82) <0.001
I had chosen the same follow-up for myself 1.0 (0.20) 2.1 (1.00) <0.001 1.1 (0.22) 2.1 (0.99) <0.001
They take enough time for me 1.0 (0.00) 1.3 (0.58) 0.03 1.1 (0.31) 1.3 (0.65) 0.32
Rating of item (1e10, 10 ¼ best)
Overall satisfaction 8.5 (1.03) 7.1 (1.18) <0.001 8.5 (0.98) 6.9 (2.38) 0.01
Extent of burden follow-up visit 8.5 (1.42) 5.2 (2.69) <0.001 8.8 (0.98) 4.8 (2.64) <0.001
Satisfaction on item (1e5, 1 ¼ most satisfied)
All items listed below together 1.6 (0.45) 2.2 (0.62) <0.001 1.7 (0.49) 2.1 (0.65) 0.07
Care is readily available 1.7 (0.64) 2.2 (1.03) 0.04 1.7 (0.64) 2.1 (0.79) 0.16
Knowledge of the physician/nurse 1.5 (0.51) 1.8 (0.53) 0.03 1.6 (0.51) 1.8 (0.45) 0.35
Confidence given by physician/nurse 1.5 (0.51) 1.8 (0.81) 0.08 1.6 (0.60) 2.1 (0.79) 0.06
Management of physical complaints 1.8 (0.59) 2.2 (0.78) 0.14 1.7 (0.56) 2.0 (0.95) 0.35
Information given by physician/nurse 1.7 (0.48) 2.2 (1.03) 0.03 1.8 (0.62) 2.1 (0.83) 0.28
Advices given by physician/nurse 1.6 (0.51) 2.3 (0.87) <0.001 1.9 (0.58) 2.2 (0.83) 0.29
Answers you get from physician/nurse 1.6 (0.50) 2.2 (0.83) <0.001 1.8 (0.62) 2.3 (0.97) 0.12
How the physician/nurse involve you in
careplanning
1.6 (0.57) 2.3 (0.85) 0.01 1.9 (0.58) 2.3 (0.97) 0.21
Support you receive from physician/nurse 1.6 (0.58) 2.3 (0.92) 0.01 1.8 (0.52) 2.3 (0.89) 0.04
The values highlighted in bold are statistically significant (P < 0.01).
aStudent’s t-test.
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follow-up group (35 outpatient clinic visits
and 45 telephone consults) (Fig. 2). Of these
visits, 157 (59%) and 47 (59%), respectively,
were regular visits and 111 (41%) vs. 33
(41%) were extra visits initiated by the patient,
the relative, or the nurse/physician. In the
conventional medical follow-up group, moreFig. 2. Characteristics of 348 home care visits, out-
patient clinic visits, or telephone consults for 66 pa-
tients (first four months of follow-up).regular visits were replaced by telephone con-
tacts (17 visits [36%] vs. two visits [1%] in
nurse-led follow-up group). Ten patients
(28%) from the nurse-led follow-up group
were referred to the outpatient clinic for a visit
with the physician.
Costs of a nurse-led follow-up visit per pa-
tient were 38% lower than those of a conven-
tional follow-up visit (V89.97 nurse-led visit
vs. V144.48 conventional medical follow-up
visit) (Table 4). Overall, within the four first
months, costs for the nurse-led follow-up strat-
egy were V336.91 vs. V144.48 per patient for
conventional medical follow-up visits because
of the higher volume of visits in the nurse-
led group.
On average, patients in the nurse-led follow-
up group had a slightly higher number of con-
tacts with GP compared with patients in the
conventional medical follow-up group (nurse-
led follow-up, median 6.0 contacts [IQR
2.75e11.0] vs. conventional medical follow-
up, median 4.0 contacts [IQR 1.50e7.50];
P ¼ 0.11) and a similar number of hospital
admissions (nurse-led follow-up, median 1.0
admission [IQR 0.00e1.25] vs. conventional
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526 Vol. 47 No. 3 March 2014Uitdehaag et al.medical follow-up, median 1.0 admission [IQR
0.00e1.00]; P ¼ 0.91), within the first four
months (Fig. 3).Discussion
This study shows that palliative care for pa-
tients with upper GI cancer can be provided
at home by specialized oncology nurses with
high patient satisfaction. Patients as well as
their relatives were highly satisfied with this
type of nurse-led follow-up. Our findings also
document that this strategy is less costly per
visit than the conventional medical follow-up
strategy, and patients’ QoL and contacts with
GP and hospital care are similar to conven-
tional medical follow-up (Fig. 3).
The higher level of satisfaction is largely de-
termined by the fact that the home visits were
perceived as less burdensome compared with
the visits to the outpatient clinic. This is prob-
ably related to the burden of travel to the hos-
pital, delays in physicians’ schedules, and the
fact that most patients prefer to receive pallia-
tive care at home and prefer to die at home.21
This could also explain why more patients in
the conventional medical follow-up group
ended the study before death (30%) than pa-
tients in the nurse-led group (8%). Further-
more, we found a difference in travel time
between included patients from both groups.
This was not the case when we analyzed the dif-
ference in travel time between the two groups
of all 138 randomized patients. Therefore, pa-
tients with conventional medical follow-up
with a further distance between home and hos-
pital had ended participation in the study ear-
lier after study entry.
The higher level of satisfaction in the nurse-
led follow-up group can further be explained
by the fact that patients and relatives appreci-
ated the nurses’ care more than physicians’
care.22 It has been suggested that quality of
care by nurses is better at this disease stage be-
cause nurses may deal with broader aspects of
the health care experience, rather than con-
centrating solely on treatment of the dis-
ease.11,22 A high level of satisfaction with
nurses’ care was found in two reviews on substi-
tution of doctors by nurses in cancer care and
in primary care.23,24 Chapple et al.25 found
that patients highly valued palliative care by
Fig. 3. Health care consumption during four months of follow-up.
Vol. 47 No. 3 March 2014 527Nurse-Led vs. Medical Follow-Upnurses, particularly their advice on practical
matters, information on their disease, emo-
tional support, advice on symptoms, help
with communication, and that nurses’ help
was readily available. In addition, continuity
of care in this study was probably better main-
tained by the nurse. In the outpatient clinic,
there was a high rotation of junior medical
staff, although some doctors made sure that
they always saw the patient themselves. Never-
theless, there are patients who may feel more
confident with follow-up given by a doctor.26
In our study, this involved 14% (n ¼ 9) of
the patients refusing participation and 3%
(n ¼ 2) of the patients who at baseline pre-
ferred conventional medical follow-up over
nurse-led follow-up.
Despite the higher satisfaction in the nurse-
led group, there was no difference in QoL
between both groups. It may not be realistic
to assume that QoL at this stage of the disease
would be significantly influenced by a visit
from a nurse once a month.27 Previous studies
on the impact of palliative home care teams
and coordinating nurses on patients’ QoL28
and on the effectiveness of nurse-led follow-
up for patients with cancer23,29,30 revealed sim-
ilar results. A review by Corner31 found that in
situations where the goals of nurse-led initia-
tives were to improve quality of care, this out-
come was not always achieved. This may havebeen influenced by the short duration of
follow-up, given the rapid death of a consider-
able proportion of patients,32 or by the possi-
bility that the instruments used were not
sufficiently sensitive to provide relevant infor-
mation at this level.33
The nurse-led follow-up did not interfere
with existing standard health care structures.
In instances where GP had a key role in the
provision of palliative care, this was not
changed. All GPs received a letter from the
study coordinators with information about
the study and the randomization procedure.
Shortly after that, if the patient was random-
ized to nurse-led follow-up, the nurse con-
tacted GP. GPs generally appreciated this and
consented to the study, even more so if they
had insufficient knowledge about upper GI
cancer and/or specialist treatments (such as
stent placement), and they noted that the
nurse was readily available for professional
advice and support. So we assume that the
nurse-led follow-up seems to complement the
general GP follow-up, just as the conventional
medical follow-up has done in the past.34
Per visit, we found a lower cost for the
nurses’ home visits in comparison with the
cost of the outpatient clinic visit. However,
the total follow-up cost of the nurse-led strat-
egy was more expensive than standard care
during the four first months of follow-up.
528 Vol. 47 No. 3 March 2014Uitdehaag et al.This was mainly because patients in the nurse-
led group had more regular visits. We assumed
that patients in this phase of their disease had
a need for close monitoring and support for
symptom control; therefore, our nurse-led
protocol included at least one visit each
month. A higher frequency revealed no signif-
icant changes in symptom burden or QoL. It is
unclear if the higher level of satisfaction was
caused by more visits. Therefore, further re-
search on the frequency and the duration of
visits is necessary in a cost utility study. Because
the costs are largely determined by travel time
and travel expenses, a study also should inves-
tigate if the home-based follow-up can be per-
formed by nurses with less travel time and
costs (e.g., community nurses) or by innova-
tive interventions such as tele-health.
Limitations
Six methodological issues merit discussion.
First, missing data may have biased the results.
Palliative care research is known to be ham-
pered by methodological challenges related
to attrition and missing data because of pro-
gressive illness and death. However, we found
no changes in our results after performing
a sensitivity analysis. Second, findings also
may have been biased by the fact that a quarter
of the questionnaires were completed with the
help of a relative or friend. However, the likeli-
hood of such bias was limited because the form
elicited patient reports regardless of who com-
pleted it. Third, the information on health
care use could have been biased by the extent
to which patients were able to remember
events. However, we used a diary to provide
an immediate update after every event, thus re-
ducing the influence of memory. Fourth, the
generalizability of our results is unknown. Be-
fore the one and a half month follow-up, 58
patients were lost to follow-up, mainly as the
result of progression of disease with deteriora-
tion and death, with related poor QoL scores.
Furthermore, 53% of the patients refusing
study participation probably had a poorer per-
formance status as they found participating
too burdensome. In addition, we did not in-
clude non-Dutch speaking patients in the
study, given the fact that we needed input by
means of questionnaires. Fifth, we took into ac-
count the problem of multiple testing and,
therefore, used a two-sided P-value of 0.01.This might not have been conservative
enough. It is possible that differences with
a P-value slightly below 0.01 are a result of mul-
tiple testing. Finally, the study was probably un-
derpowered. In our center, approximately 200
patients with esophageal, pancreatic, and hep-
atobiliary cancer undergo palliative treatment
annually. It was expected that at least 60%
(120 patients) would consent to participation
in this study. Taking into consideration an ini-
tial phase of three months, within 18 months
a total of 150 patients (esophageal/gastric car-
cinoma [n ¼ 50], pancreatic/duodenum carci-
noma [n ¼ 50], and hepatobiliary carcinoma
[n ¼ 50]) were expected to be eligible for ran-
domization. In fact, in three years, only 204
patients were found to be eligible for palliative
treatment. This is most likely the result of the
fact that the treating physicians quite often
concluded that patients were still not in the
palliative phase of their illness and, therefore,
did not invite patients to participate in this
study. It was decided to close inclusion of
patients for the study after three years as bud-
get was depleted. Therefore, the results of this
study cannot be generalized to all incurable GI
cancer patients.Conclusion
Nurse-led follow-up at home resulted in un-
changed satisfaction over time in upper GI
cancer patients and their relatives receiving
palliative care, whereas conventional medical
follow-up in an outpatient clinic resulted in
a decrease in satisfaction. The intervention
had no significant effect on QoL and health
care consumption and was less costly. The re-
sults suggest that physician-led follow-up is in-
terchangeable with nurse-led follow-up,
although it is unclear which frequency for
visits is desirable. A cost utility study is neces-
sary to determine the preferred frequency
and duration of home visits. This information
can be useful in developing hospital-based pal-
liative care follow-up program and improving
palliative care for patients and relatives.Disclosures and Acknowledgments
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Problem-Oriented Nursing Care Plan During Home Visits
Assessment of symptoms 
and problems
If necessary, simple physical 
examination
Determine expected nursing 
outcome
Nursing diagnosis?
ye
s
Nursing interventions:
* provide support
*educate and provide advises
no
Consultation medical 
physician Erasmus MC
Evaluation
Inform GP
yes
n
o
Referral GP?
Other nursing intervention as 
a result of this consultation/
referral
yes
Feedback to the GP and 
medical physician
n
o
yes
no
Referral, consultation, 
intervention by GP
Referral medical physician? Make an appointment with 
medical physician
n
o
